The Lancet Gastroenterology & Hepatology

🌍 IBD: a global disease needs global solutions As part of the ongoing The Lancet Gastroenterology & Hepatology Global IBD Commission, the Commissioners invite you to participate in the Global IBD Preparedness Survey. The survey should take approximately 20 minutes; it is confidential and in multilingual format. ✍ Participate now at https://lnkd.in/givUs2ah 📨 ibdpreparednesssurvey@gmail.com #gastroenterology #inflammatoryboweldisease #IBD #medicine #healthcare S Sebastian Anuraag Jena Vishal Sharma Charlie Lees Britta Siegmund Paulo Kotze Natália Queiroz Rupa Banerjee Siew Ng Leolin Katsidzira Sara El Ouali Mahmoud Mosli Jalpa Devi Beatriz Gros Tina Aswani-Omprakash, MPH The Lancet Gastroenterology & Hepatology

The April issue of The Lancet Gastroenterology & Hepatology is out now at https://lnkd.in/eKVUYNBP! We have two Editorials this month, the first looking at the effects of the Trump administration's decimation of the global health infrastructure on the elimination of viral hepatitis (https://lnkd.in/eBu9aueG), and the second introducing a Series of papers in the issue on the management of hepatocellular carcinoma (https://lnkd.in/e-SgY3HH); the Series forms the basis of this month's cover, by Vito Ansaldi. Our Comment section features pieces on reducing use of diagnostic GI endoscopy and on the underestimation of alcohol intake in those with MetALD and ALD, plus the usual expert opinion on the research articles in the issue. This month's News & In Focus sections include a round up of highlights of the literature and a patient perspective on living with gastro-oesophageal reflux disease. Amongst our research articles this month, we feature the ATTENTION trial of early antiviral treatment for individuals with chronic hepatitis B and moderate to high viraemia (https://lnkd.in/ewbVRZXy), the PET-HCC01 study of the use of PET-CT in staging and management of newly diagnosed hepatocellular carcinoma (https://lnkd.in/eqThWVMt), a study estimating the global burden of hepatitis C in people who inject drugs, and a meta-analysis that informed the cutoffs for non-invasive diagnosis and staging of liver fibrosis and cirrhosis in the 2024 WHO hepatitis B guidelines. Enjoy! #hepatology #gastroenterology #oncology #medicine #healthcare Ruth Zimmermann Aleksander Krag Nikolaj Torp Ming-Lung Yu Jonggi Choi Suk-Joon Hyung Chien-Hung Chen Jean-Charles Nault Myriam Wartski Mohamed Bouattour Adelina Artenie Jack Stone Louisa Degenhardt Gregory Gores Jason Grebely Behzad Hajarizadeh Daniel Low-Beer Matthew Hickman Peter Vickerman Antonio Liguori Mirko Zoncapè Giovanni Casazza Philippa Easterbrook Emmanuel Tsochatzis Prof. Dr. Arndt Vogel Grainne O'Kane MB, BCH, BAO, MRCPI, MD Dr. Gonzalo Sapisochin Justin Guan Zhi-Cheng JING Gao-Jun Teng Stephanie Dudzinski Reena Engineer Nina Sanford Chandan Guha Ted Hong Laura Dawson Eugene Koay

After a long break from podcasting, I hosted the latest episode of The Lancet Gastroenterology & Hepatology In Conversation With... while Hugh Thomas took a well-earned break. I had the pleasure of chatting with Dr John Chia, study co-chair of the ASCOLT study to discuss the role of adjuvant aspirin in colorectal cancer, with insights into both the ASCOLT study and the ALASCCA trial, which was presented recently at ASCO GI. #colorectalcancer #podcast #gastroenterology #oncology #healthcare #medicine

Is there a role for PET-CT in staging and treatment modification in patients with newly diagnosed hepatocellular carcinoma? In a prospective, multicentre study, Jean-Charles Nault and colleagues assessed whether the use of [¹⁸F]fluorodeoxyglucose (FDG) and [¹⁸F]fluorocholine (FCH) PET-CT altered treatment decisions made in multidisciplinary team meetings for patients with newly diagnosed hepatocellular carcinoma. Participants had initially undergone contrast-enhanced liver MRI and liver, chest, and pelvis CT scans, followed by FDG and FCH PET-CT. The initial MRI and CT scans informed the first tumour staging and treatment decision, blind to the results of the PET-CT scans. The multidisciplinary team subsequently re-assessed tumour staging and their treatment decision after the PET-CT results were revealed. While the use of PET-CT revealed the presence of potential new lesions in 19 (9%) of the 215 included patients and resulted in modification of BCLC stage in ten, planned treatment was modified for only four (2%) of patients, well below the prespecified 10% threshold for clinical significance. The authors conclude that the routine use of PET-CT for tumour staging in patients with a first diagnosis of hepatocellular carcinoma appears to have limited clinical value, and that guidelines should continue to recommend use of morphological imaging such as MRI and CT scans for staging. Article: https://lnkd.in/edzvRgD9 Comment: https://lnkd.in/ezsh83hi #hepatology #oncology #radiology #medicine #healthcare Marouane BOUBAYA Myriam Wartski Anthony Dohan Michael Soussan Julia Roux Christian Sengel Marie Lequoy Yves Menu Denis Mariano-Goulart Boris Guiu Alain LUCIANI Marco Dioguardi Burgio Mathilde Wagner Sébastien Mulé Manon Allaire Sabrina Sidali Audrey Coilly Florent Besson Maïté Lewin Hélène REGNAULT Giuliana Amaddeo Maxime Ronot Coralie Bloch Rachida Lebtahi Julia CHALAYE Mohamed Bouattour

Feb 28 marked the start of Ramadan 2025, the nineth month of the Islamic calendar, during which Muslims who are able observe a month of fasting from sunrise until sunset each day. There is, however, no current health-related consensus on the management of people with gastrointestinal or hepatobiliary disorders who opt to fast during Ramadan. To address this, Muhammad Usman and colleagues developed a review of the effects and safety of Ramadan intermittent fasting among people with gastrointestinal and hepatobiliary conditions to provide practical guidance for health-care professionals. Read the review here: https://lnkd.in/gMMnuMH5 #gastroenterology #hepatology #medicine #healthcare #Ramadan Aida Jawhari Nazim Ghouri Dr Salman Waqar Bilal Hameed

Hepatocellular carcinoma is a leading cause of cancer-related death globally. The treatment of hepatocellular carcinoma is complex, with diverse therapeutic approaches and their combinations available across tumour stages, and the need to navigate the underlying liver disease. Our new Series explores three key areas in the modern management of hepatocellular carcinoma. The first paper examines the personalisation of surgery for patients with hepatocellular carcinoma, which remains the primary curative therapeutic option. The second paper explores how recent advances with immunotherapy-based systemic therapies could be combined with locoregional therapies, while the last paper discusses the emerging role of external-beam radiotherapy and its place in treatment algorithms. https://lnkd.in/eUSSzwYN #hepatology #oncology #hepatocellularcarcinoma #livercancer #medicine #healthcare Christian T. J. Magyar, MD Luckshi Rajendran Vanessa Banz Prof. Dr. Arndt Vogel Grainne O'Kane MB, BCH, BAO, MRCPI, MD Grainne O'Kane MB, BCH, BAO, MRCPI, MD Chirin Al Dalati, MD Dr. Gonzalo Sapisochin Justin Guan Zhi-Cheng JING Hai-Dong Zhu Gao-Jun Teng Stephanie Dudzinski Reena Engineer Nina Sanford Chandan Guha Ted Hong Laura Dawson Eugene Koay

Alcohol consumption is a leading risk factor for disease, accounting for almost 10% of global deaths among individuals aged 15–49 years. An estimated 400 million people are affected by alcohol use disorder, a chronic, relapsing brain disease that is often associated with other comorbid psychiatric and medical conditions. Alcohol-related liver disease is a direct consequence of alcohol use disorder, yet there are multiple barriers to providing integrated management to patients with alcohol use disorder. In a Review, Luis Antonio Diaz Piga and colleagues examine the different aspects of alcohol use disorder management and provide updated evidence for the daily clinical practice of gastroenterologists, hepatologists, and related health-care providers. Read the full paper here: https://lnkd.in/eH6Z6cBT Daniel König Gonzalo Andrés Mieres Fuentealba Ramon Bataller Gerald Scott Winder Lorenzo Leggio Juan Pablo Arab #hepatology #gastroenterology #psychology #psychiatry #primarycare #healthcare #medicine #alcohol

New Editorial - US policy changes put elimination of viral hepatitis at high risk "This unprecedented attack on the global health infrastructure risks further derailing efforts to eliminate viral hepatitis and must be stopped." https://lnkd.in/enh7fEy5 #viralhepatitis #hepatology #infectiousdiseases #medicine #policy #globalhealth The World Hepatitis Alliance Hepatitis B Foundation The Hepatitis Fund Coalition for Global Hepatitis Elimination

The March issue of The Lancet Gastroenterology & Hepatology is out today at https://lnkd.in/eKVUYNBP! This month's cover by Vito Ansaldi is based on one of the research articles in this issue: the ASCOLT trial, a phase 3 randomised trial exploring the effect of the use of aspirin after completion of standard adjuvant therapy for patients with colorectal cancer. This month's Editorial discusses alcohol, cancer risk, and efforts to increase awareness of the link between the two in the general public. Our Comment section includes the customary expert opinion pieces linked to the research articles in the issue plus a comment examining efforts to eliminate viral hepatitis in Ethiopia, and thank all who reviewed papers for us over the past year. In terms of research articles, in addition to ASCOLT, this issue also includes the results of a phase 2 induction trial of tamuzimod, a new S1PR modulator, in patients with moderately to severely active ulcerative colitis, an individual patient data meta-analysis comparing the use of antibiotics with appendicectomy for adults with acute appendicitis, and data from the maintenance phase of the VEDOKIDS study, a prospective cohort study assessing the use of vedolizumab in paediatric IBD. We also have two excellent reviews, the first discussing the liver-brain axis in MASLD and the second looking at IBD in South Asia. #gastroenterology #hepatology #medicine #healthcare Mingyang Song Adewale Adisa Elizabeth A. Spencer, MD, MS Hailemichael Desalegn Mekonnen Nassim HAMMOUDI Matthieu Allez Andrew K. Nguyen MD, MBA Christopher Li Wai Suen Geert DHaens Eva Segelov Han Chong Toh Bruce Sands Remo Panaccione Vipul Jairath Jochem Scheijmans Marja Boermeester Anne Catrine Daugaard Mikkelsen Kristoffer Kaae Kjærgaard Karen Louise Thomsen Anuraag Jena Carrie Levinson Vishal Sharma Parakkal Deepak, MD, MS, FACG Tina Aswani-Omprakash, MPH Jean-Frederic Colombel Manasi Agrawal

Last chance to join us in Shanghai for The Lancet Summit: cancer control in China 🇨🇳 The Summit’s multi-track programme brings together more than 40 expert speakers who will share insights into cancer control in breast, gastrointestinal, and lung cancers and COPD. There will also be opportunities to network, explore poster sessions, and attend the Conference Gala Dinner. Find out more and register today ➡️ https://lnkd.in/ecWJc24A